secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001725160-24-000087
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Melissa Epperly resigns; President Cam Gallagher named interim CFO
----------------------------------------------------------------------

- Melissa Epperly resigned as CFO, treasurer, principal financial and accounting officer effective April 5, 2024.
- President Cam Gallagher appointed interim CFO, treasurer and principal financial officer; VP Finance Vincent Vultaggio named interim principal accounting officer.
- Chief Business Officer Kyle Rasbach will oversee Investor Relations on an interim basis.
- Company is conducting a search for a new permanent CFO.
- Epperly eligible for severance benefits under her amended employment agreement, subject to execution of a release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000087/0001725160-24-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000087/zntl-20240405.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer